AAV-Q Platform for rcAAV Assay

Introduction

AAV continues to lead the field of in vivo gene delivery, vector safety and regulatory compliance have never been more critical. Among the key concerns during AAV vector production is the potential generation of replication-competent AAV (rcAAV) — a rare but significant contaminant that can compromise therapeutic safety, product quality, and clinical trial outcomes. The Food and Drug Administration (FDA) requires that AAV products be screened for rcAAVs to ensure the safety of gene therapy products. 

At AAVnerGene, we developed AAV-Q Platform, which works for  for both AAV TCID50 and rcAAV assay. 

AAV-Q Platform

The AAV-Q Platform includes three specialized cell lines, two quantitative assays, and one adenoviral vector, providing a complete and standardized system for AAV infectivity and rcAAV analysis.

AAV-Q System for AAV potency and rcAAV assay

Three Cell Lines:

  • HEK293R: AAVR overexpression based on HEK 293A cells;
  • HEK293RR:  Rep overexpression based on HEK 293R cells;
  • HEK293Rd: Optimized for Rd-Ad5 production;

One Ad vector:

  • Rd-Ad5：Replication deficient in HEK 293A, but not in HEK293Rd cells;

Two Assays:

  • AAV TCID50 Assay: Measures AAV potency or infectious titer using HEK293RR cells with Rd-Ad5;
  • rcAAV Assay: Detects replication-competent AAVs using HEK293R cells with Rd-Ad5;

Key Features of AAVnerGene's rcAAV assay

  • Ultra-sensitive: Detects a single-copy;
  • Quick results: Turnaround within one week;
  • Broadly compatible: works with most AAV serotypes;
  • Safe design: Uses Rd-Ad5 instead of wtAd5;
  • Cost-efficient: streamlined qPCR workflow;
  • Highly consistent: Controlled assay conditions;
  • Reliable & robust: Low variability and high reproducibility;
rcAAV and AAV potency assay

Products and Services of rcAAV assay

Products/ServicesSpecificationPriceOrder
HEK293R HEK293A stably expression AAVR geneLicenseIn stock
Rd-Ad5

≥1E8 TU/ml, 100 μl, Replication deficient in HEK293 cell 

$1999In stock
rcAAV assayFull scale of  rcAAV assay and report$50002-3 weeks

What Is rcAAV?

rcAAV (replication-competent AAV) refers to AAV particles that have regained the ability to replicate in the presence of a helper virus (e.g., adenovirus). It is wild-type like AAV.  This can occur unintentionally during AAV vector manufacturing, typically due to recombination events between plasmids encoding AAV Rep and Cap genes and the ITR-flanked transgene.

Although rcAAV is rare in well-optimized systems, its presence poses several concerns:

  • Uncontrolled replication in vivo (especially in immunocompromised hosts)

  • Potential integration into host genomes

  • Increased immunogenicity

  • Regulatory non-compliance

rcAAV generation

rcAAV assay service at AAVnerGene

This service is for customers who need accurate rcAAV titer of the AAV virus for research and therapeutic purpose. The FDA’s recommended level for rcAAV in AAV products is generally less than 1 rcAAV per 1e8 vector genomes, according to Regulations.gov.

rcAAV assay protocol

(1) Thawing Frozen Cells

  • Retrieve the cryovial containing frozen HEK293R cells from the shipment package or liquid nitrogen storage.

  • Immediately place the vial into a 37°C water bath.

  • Gently swirl the vial in the water bath for rapid thawing, ensuring the process takes less than 1 minute. Remove the vial when only a small ice crystal remains.

  • Disinfect the outside of the vial with 70% ethanol and transfer it into a laminar flow hood.

  • Transfer the cell suspension into a 10 cm culture dish containing 10 mL of pre-warmed DMEM supplemented with 10% FBS and 1% Penicillin-Streptomycin (PS).

  • After 6–12 hours, once the cells have attached, replace the medium with fresh pre-warmed DMEM containing 10% FBS and 1% PS.

  • Within 48 hours, the HEK293R cells should reach confluency in the dish.

(2) Infecting HEK293R with Rd-Ad5 adenovirus

  • Harvest and dissociate HEK293R cells. Resuspend the cells in complete growth medium at a density of 6.0 × 10⁵ viable cells/mL, preparing a total volume of 6 mL.

  • Add 36 µL of 1.0 × 10⁸ IFU/mL Rd-Ad5 adenovirus to the 6 mL cell suspension, achieving a final MOI=10.

  • Dispense 50 µL of the cell-virus mixture into each well of a 96-well culture plate.

  • Incubate the plate at 37°C with 5% CO₂ for 24 hours. 

  • Check EGFP expression under microscope. 

(3) Serial Dilution Setup for rAAV Titration
(Example using AAV2 with a genome titer of ~1.0 × 10¹³ gc/mL)

  • Label 10 × 1.5 mL Eppendorf tubes (D1 to D10) and 
    • add 90 µL of complete cell culture medium to D1
    • add 900 µL of complete cell culture medium to D2-D10.

  • D1 (1×10¹): Add 10 µL of the original AAV stock to the first dilution tube (already containing 90 µL medium).

  • D2 (1×10²): Transfer 100 µL from D1 to D2, mix well.

  • D3 (1×10³): Transfer 100 µL from D2 to D3, mix well.

  • D4 (1×10⁴): Transfer 100 µL from D3 to D4, mix well.

  • D5 (1×10⁵): Transfer 100 µL from D4 to D5, mix well.

  • D6 (1×10⁶): Transfer 100 µL from D5 to D6, mix well.

  • D7 (1×10⁷): Transfer 100 µL from D6 to D7, mix well.

  • D8 (1×10⁸): Transfer 100 µL from D7 to D8, mix well.

  • D9 (1×10⁹): Transfer 100 µL from D8 to D9, mix well.

  • D10 (1×10¹⁰): Transfer 100 µL from D9 to D10, mix well.

(4) AAV TCID₅₀ Assay Setup
(Example using rAAV2 with ~1.0 × 10¹³ gc/mL genome titer)

  • Confirm Adenoviral Infection
    • Inspect HEK293R cells in the 96-well plate under a fluorescence microscope.

    • Expected outcome: Uniform and strong GFP expression across all wells, with no signs of cell death or detachment. This confirms effective Ad5d-Cre-GFP infection.

  • Add Serial Dilutions of Test AAV2

    • Add 50 µL of AAV2 dilutions (D7 to D10, corresponding to 1×10⁷ to 1×10¹⁰ dilution) to designated wells.

    • For each dilution, use one full row with 10 replicate wells per row (columns 1–10).

  • Set Up Controls

    • Add 50 µL of complete medium (no AAV) to wells 11 and 12 in each row as the adenovirus-only negative control.

  • Incubation

    • Return the plate to a 37°C, 5% CO₂ incubator.

    • Incubate for 72 hours to allow sufficient time for AAV replication and transgene expression.

(5) Genomic DNA Extraction and Real-Time PCR Assay

  • Confirm Adenoviral Infection

    • Examine the HEK293R cells in the 96-well plate under a fluorescence microscope.

    • Expected result: Uniform and robust GFP expression across all wells, with no signs of cell death or cell detachment.

  • Cell Lysis and Protein Digestion

    • Add 20 µL of 10× Proteinase K digestion buffer (1% SDS, 10 mM EDTA, 10 mM PBS, pH 8.0) to each well.

    • Add Proteinase K to a final amount of 25 µg per well.

  • Incubation for Lysis

    • Incubate the plate at 37°C for 1 hour to allow complete digestion.

  • Confirm Cell Lysis

    • Re-examine the plate under a microscope.

    • Expected result: Complete cell lysis in all wells, with no visible cell patches remaining.

  • Inactivate Proteinase K

    • Transfer the entire lysate (~120 µL per well) to a 96-well PCR plate.

    • Heat at 95°C for 10 minutes to inactivate Proteinase K.

  • Dilution for PCR

    • Prepare a fresh 96-well PCR plate by adding 90 µL of nuclease-free water to each well.

    • Transfer 10 µL of the heat-inactivated lysate from each corresponding well into the new plate.

  • This results in a 10× dilution, suitable for downstream real-time PCR analysis.

(6) Setup real-time PCR Assay and analyze the data

  • Perform real-time PCR using your preferred system. Use 2 µL of diluted lysate from each well as the template.

  • After the run, calculate the negative threshold using the following formula:
    Threshold Ct = Average Ct of all negative control wells − (3 × standard deviation)

  • For each sample well, if the Ct value is lower than the calculated threshold, the sample is considered positive for AAV infection.

  • Analysis the data.